BRPI0417932A - lipólise medicamentosa de acúmulo de gordura - Google Patents

lipólise medicamentosa de acúmulo de gordura

Info

Publication number
BRPI0417932A
BRPI0417932A BRPI0417932-3A BRPI0417932A BRPI0417932A BR PI0417932 A BRPI0417932 A BR PI0417932A BR PI0417932 A BRPI0417932 A BR PI0417932A BR PI0417932 A BRPI0417932 A BR PI0417932A
Authority
BR
Brazil
Prior art keywords
fat accumulation
lipolysis
accumulation drug
drug
fat
Prior art date
Application number
BRPI0417932-3A
Other languages
English (en)
Inventor
Peter Boderke
Matthias Gossel
Walter Kamm
Karl-Heinz Nietsch
Rainer Pooth
Juergen Sandow
Joerg Hager
Gerhard Sattler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0417932A publication Critical patent/BRPI0417932A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Abstract

"LIPóLISE MEDICAMENTOSA DE ACúMULO DE GORDURA". A presente invenção refere-se a preparações aquosas contendo pelo menos um fosfolipídio e/ou pelo menos um ácido biliar e um componente que auxilia a decomposição de gordura, como riboflavina e água, são apropriadas para preparação de medicamentos para eliminação de acúmulo subcutâneo de gordura e levam à regressão de panículo adiposo resistentes a dietas.
BRPI0417932-3A 2003-12-22 2004-12-11 lipólise medicamentosa de acúmulo de gordura BRPI0417932A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10361067A DE10361067A1 (de) 2003-12-22 2003-12-22 Medikamentöse Lipolyse von Fettansammlungen
PCT/EP2004/014134 WO2005063169A2 (de) 2003-12-22 2004-12-11 Medikamentöse lipolyse von fettansammlungen

Publications (1)

Publication Number Publication Date
BRPI0417932A true BRPI0417932A (pt) 2007-04-17

Family

ID=34673059

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417932-3A BRPI0417932A (pt) 2003-12-22 2004-12-11 lipólise medicamentosa de acúmulo de gordura

Country Status (11)

Country Link
EP (1) EP1699490A2 (pt)
JP (1) JP2007515439A (pt)
KR (1) KR20060121238A (pt)
CN (1) CN1897974A (pt)
AU (1) AU2004308072A1 (pt)
BR (1) BRPI0417932A (pt)
CA (1) CA2551474A1 (pt)
DE (1) DE10361067A1 (pt)
IL (1) IL176026A0 (pt)
MX (1) MXPA06006645A (pt)
WO (1) WO2005063169A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660172T3 (es) 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
DK1845938T3 (da) * 2005-02-08 2019-07-01 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Fremgangsmåder og relaterede sammensætninger til reduktion af fedt og stramning af hud
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
FR2937554B1 (fr) * 2008-10-27 2010-11-12 Yves Crassas Solutions salines aqueuses pour la destruction de tissus graisseux
CA2754008C (en) * 2009-03-02 2016-04-26 Doris Hexsel Medicinal cosmetic lipoatrophy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP5747820B2 (ja) 2009-08-25 2015-07-15 株式会社 メドレックス ホスファチジルコリンの経皮投与組成物とその製造方法
DE102010028365A1 (de) 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
WO2013028177A1 (en) * 2011-08-23 2013-02-28 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
ES2882496T3 (es) * 2014-03-21 2021-12-02 Nestle Sa Administración materna de vitamina B2 para prevenir un aumento de adiposidad, sobrepeso u obesidad del hijo
RU2736974C1 (ru) * 2017-04-21 2020-11-23 Ами Фарм Ко., Лтд. Инъецируемая композиция для уменьшения локализованного жира без болевого синдрома, отёка и побочных эффектов и способ ее получения
KR102093872B1 (ko) * 2017-07-03 2020-03-27 진호성 지방제거용 주사제 조성물 및 이의 제조방법
JP6356329B2 (ja) * 2017-09-27 2018-07-11 キテラ バイオファーマシューティカルズ，インコーポレイテッド デオキシコール酸およびその塩類の製剤
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
CN109674696A (zh) * 2018-03-27 2019-04-26 上海同柏生物科技有限公司 一种用于腹部脂肪降解技术及其制剂与应用
CN110302082A (zh) * 2018-03-27 2019-10-08 上海同柏生物科技有限公司 用于减少身体脂肪沉积的技术及组合物制剂与应用
JP2021186680A (ja) 2020-06-01 2021-12-13 コスメディ製薬株式会社 美容用マイクロニードルアレイ
WO2022019187A1 (ja) * 2020-07-20 2022-01-27 コスメディ製薬株式会社 美容用外用剤及び化粧料
KR102513115B1 (ko) * 2020-12-18 2023-03-22 주식회사 레시텍 리토콜릭산을 포함하는 국소지방 감소용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10349979B4 (de) * 2003-10-24 2006-05-18 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale Lipolyse

Also Published As

Publication number Publication date
MXPA06006645A (es) 2006-08-31
WO2005063169A2 (de) 2005-07-14
CA2551474A1 (en) 2005-07-14
IL176026A0 (en) 2006-10-05
DE10361067A1 (de) 2005-07-14
JP2007515439A (ja) 2007-06-14
KR20060121238A (ko) 2006-11-28
AU2004308072A1 (en) 2005-07-14
WO2005063169A3 (de) 2006-05-04
EP1699490A2 (de) 2006-09-13
CN1897974A (zh) 2007-01-17

Similar Documents

Publication Publication Date Title
BRPI0417932A (pt) lipólise medicamentosa de acúmulo de gordura
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BRPI0416796A (pt) compostos orgánicos
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
HK1096857A1 (en) Medicamentously targeted local lipolysis
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
MXPA06013121A (es) Metodo y composicion para el tratamiento de rinitis.
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
ATE353655T1 (de) Myo-inositol hexaphosphat zur topischen verwendung
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
BR112019007539A2 (pt) formulações para liberação entérica de agentes terapêuticos
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
PE20110066A1 (es) Dronedarona para la prevencion de la cardioversion
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
BRPI0517950A (pt) uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele
JP2004002429A5 (pt)
WO2006086992A3 (en) Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.